Unlike adults, most paediatric patients experience mild severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections, showing favourable outcomes and extremely low hospitalisation rates.1 However, if we consider frail patients, the risk of developing a severe coronavirus disease (COVID-19) increases to even life-threatening clinical scenarios.2

Due to their immunosuppressive status, transplant recipients and onco-haematological children represent a restricted but vulnerable cohort of patients exposed to high-risk outcomes.2

Currently available therapies approved by the European Medicines Agency (EMA) for early stages of infection in patients at high risk of developing a severe form of the disease include neutralising monoclonal antibodies (mAbs) and antiviral agents. However, only mAbs have been currently approved for paediatric patients …